Indibulin - CAS 204205-90-3
Catalog number: 204205-90-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H16ClN3O2
Molecular Weight:
389.83
COA:
Inquire
Targets:
Microtubule/Tubulin
Description:
Indibulin, also called D 24851, estabilizes tubulin polymerization (IC50 = 0.3 μM) and induces tumor cell cycle arrest and apoptosis. In vitro: blocking cell cycle progression at metaphase; In vivo: induce complete tumor remission in the Yoshida AH13 rat sarcoma model
Brife Description:
Estabilizes tubulin polymerization; Induces tumor cell cycle arrest and apoptosis
Appearance:
Off-white solid
Synonyms:
2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide; D 24851; D-24851; indibulin; N-(pyridin-4-yl)-(1-(4-chlorobenzyl)indol-3-yl)glycoxylamide; N-(pyridin-4-yl)-(1-(4-chlorobenzyl)indol-3-yl)glyoxylamide
Solubility:
Soluble to 25 mM in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -60℃ for long term (months to years).
MSDS:
Inquire
Density:
1.310 g/cm3
InChIKey:
SOLIIYNRSAWTSQ-UHFFFAOYSA-N
InChI:
1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)
Canonical SMILES:
C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4
1.[Molecular dynamics simulation of the tubulin dimer with cytostatics].
Varzhabetian LR, Glazachev DV, Nazarian KB. Mol Biol (Mosk). 2012 Mar-Apr;46(2):348-53.
Colchicin, podophylotoxin and indibulin are natural cytostatics that are used in the treatment of neoplasms. But applications of those compounds are rather restricted due to the high toxicity and low specificity. It seems very promising to investigate possibility to design new analogs of the above mentioned drugs that will possess higher cytostatic activity and less toxicity. For this purpose we see computer modeling experiments of tubulin and above mentioned compounds interaction as a powerful approach to design new artificial cytostatics with desired properties. In the current study the CHARMM software of protein-ligand interaction molecular dynamics method has been used. Particularly the following strategy has been applied. Molecules of the cytostatits have been positioned at several random positions around binding sites of tubulin and after energy minimization several binding sites have been identified on the tubulin macromolecule. In these binding sites structural changes that may be responsible for tubulin polymerization have been detected.
2.Side chain modifications of (indol-3-yl)glyoxamides as antitumor agents.
Antoine M1, Marchand P, Le Baut G, Czech M, Baasner S, Gunther E. J Enzyme Inhib Med Chem. 2008 Oct;23(5):686-95. doi: 10.1080/14756360802207998 .
New series of analogues of N-(pyridin-4-yl)-2-[1-(4-chlorobenzyl)-indol-3-yl]glyoxamide D-24851 were synthesized, characterized and tested for their in vitro anticancer properties. In the first series, an amino acid spacer was introduced in the glyoxamide chain of D-24851. In the second series, the glyoxamide chain was moved to positions 4 and 5 of indole skeleton. These new compounds were tested on four cancer cell lines (KB, SK-OV-3, NCI-H460 and SF-268), with promising activity for the glycine derivative.
3.Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.
Oostendorp RL1, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Invest New Drugs. 2010 Apr;28(2):163-70. doi: 10.1007/s10637-009-9244-6. Epub 2009 Apr 30.
Indibulin (ZIO-301/D-24851) is an orally applied small molecule with antitumor activity based upon destabilization of microtubule polymerization. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) as well as the dose limiting toxicity (DLT), the pharmacokinetics, safety and tolerability of orally administered indibulin as capsule formulation in patients with advanced solid tumors. Patients received a single dose of indibulin. Seven dose-levels were evaluated: 100 mg, 150 mg, 250 mg, 350 mg and 600 mg once daily (QD), 450 mg and 600 mg twice daily (BID). After a washout period, patients received indibulin at the pre-defined daily dose for 14 days every 3 weeks (multiple dose part). A total of 28 patients entered the study. Indibulin administered as capsules was generally well tolerated. The MTD was not reached. There was a disproportionate increase of the area under the plasma concentration-time curve (AUC) with dose, with declining AUC corrected for dose starting at the 250 mg dose-level.
4.Design, synthesis and cytotoxicity of novel podophyllotoxin derivatives.
Yu PF1, Chen H, Wang J, He CX, Cao B, Li M, Yang N, Lei ZY, Cheng MS. Chem Pharm Bull (Tokyo). 2008 Jun;56(6):831-4.
A series of novel podophyllotoxin derivatives were designed using association strategy and synthesized by coupling either podophyllotoxin (1) or 4beta-amino podophyllotoxin (3) with substituted indol-3-yl-glyoxyl chlorides. Their structures were identified using spectroscopic techniques. These novel derivatives have been evaluated for cytotoxicity in vitro against four human cancer cell lines with comparison to the parent compounds 1, 3 and indibulin (2). Some of the compounds (7a, 7c) showed comparable cytotoxicity to that of podophyllotoxin.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


CAS 1233948-35-0 ELR510444

ELR510444
(CAS: 1233948-35-0)

ELR510444 is a potent microtube disruptor with potential anticancer activity. ELR510444 has potent microtubule-disrupting activity, causing a loss of cellular m...

CAS 64-86-8 Colchicine

Colchicine
(CAS: 64-86-8)

Colchicine, a toxic plant-derived alkaloid extracted from plants of the genus Colchicum, inhibits microtubule polymerization (IC50 = 3.2 μM).

ACI-35

ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...

CAS 917111-49-0 Lexibulin dihydrochloride

Lexibulin dihydrochloride
(CAS: 917111-49-0)

Lexibulin dihydrochloride is an orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. It inh...

CAS 313367-92-9 UA 62784

UA 62784
(CAS: 313367-92-9)

UA 62784, under the IUPAC name 4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]fluoren-9-one, a cytotoxic microtubule inhibitor in vitro, causes reversible cell cycle ar...

CAS 35846-53-8 Maytansine

Maytansine
(CAS: 35846-53-8)

Maytansine is a cytotoxic agent, originally isolated from the Ethiopian shrub Maytenus serrata. It inhibits the assembly of microtubules by binding to tubulin a...

CAS 945771-74-4 BNC-105

BNC-105
(CAS: 945771-74-4)

BNC105 is a novel compound being developed by Bionomics as a Vascular Disrupting Agent (VDA) for treatment of cancer. VDAs are drugs that disrupt the blood vess...

CAS 518-28-5 Podophyllotoxin

Podophyllotoxin
(CAS: 518-28-5)

Podophyllotoxin, a kind of non-alkaloid toxin lignan extracted from the roots and rhizomes of Podophyllum plant, has been shown to inhibit the growth of various...

CAS 1402727-29-0 PE859

PE859
(CAS: 1402727-29-0)

PE859 is a potent dual inhibitor of tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.

CAS 1228105-51-8 DM1-SMCC

DM1-SMCC
(CAS: 1228105-51-8)

This active molecular is DM1 with a linker SMCC that can react with antibody to make antibody drug conjugate. DM1 is an antibody-conjugatable maytansinoid that ...

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 117048-59-6 Combretastatin A4

Combretastatin A4
(CAS: 117048-59-6)

Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demons...

CAS 71486-22-1 Vinorelbine

Vinorelbine
(CAS: 71486-22-1)

Vinorelbine, also called Navelbine, a 5′NOR semisynthetic vinca alkaloid which arrests tumor cell growth in metaphase by binding to tubulin and preventing form...

CAS 41179-33-3 CMPD-1

CMPD-1
(CAS: 41179-33-3)

CMPD-1, also called MK2a Inhibitor, inhibits tubulin polymerisation. It inhibit p38α-mediated MK2a phosphorylation (apparent Ki = 330 nM).

CAS 183133-96-2 Cabazitaxel

Cabazitaxel
(CAS: 183133-96-2)

Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%.

CAS 189453-10-9 Epothilone D

Epothilone D
(CAS: 189453-10-9)

Epothilone D is a natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubu...

C2N 8E12

C2N 8E12 is a humanized antibody that currently in clinical development works to protect against Alzheimer’s disease by stimulating the immune system to activat...

CAS 6559-91-7 4'-Demethylepipodophyllotoxin

4'-Demethylepipodophyllotoxin
(CAS: 6559-91-7)

4'-Demethylepipodophyllotoxin is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs. It is a potent inhibitor of microtub...

CAS 141430-65-1 ABT 751

ABT 751
(CAS: 141430-65-1)

ABT 751, also called E7010, is a a novel bioavailable tubulin-binding and antimitotic agent (in neuroblastoma: IC50= 0.6–2.6 μM; in non-neuroblastoma cell line...

CAS 865-21-4 Vinblastine

Vinblastine
(CAS: 865-21-4)

Vinblastine is inhibitor of nAChR and can inhibit the formation of microtubule. It is a natural alkaloid isolated from the plant Vinca rosea Linn. It binds to t...

Chemical Structure

CAS 204205-90-3 Indibulin

Quick Inquiry

Verification code

Featured Items